The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma

✍ Scribed by Cuttner, Janet ;Wasserman, L. R. ;Martz, Georg ;Sonntag, Roland W. ;Kyle, Robert A. ;Silver, Richard T. ;Spurr, Charles ;Harley, John B. ;Wiernik, Peter M. ;Cornwell, Gibbons G. ;Falkson, Geoffrey ;Glidewell, Oliver ;Holland, James F.

• Publisher: John Wiley and Sons
• Year: 1975
• Tongue: English
• Weight: 416 KB
• Volume: 1
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950010304

✦ Synopsis

Abstract

A study was designed to evaluate the effectiveness of prednisone therapy in poor‐risk patients with multiple myeloma. Patients were treated with melphalan alone or in combination with prednisone at doses of either 0.6 mg/kg or 0.3 mg/ kg. The group of patients receiving melphalan and prednisone 0.6 mg/kg had significantly improved responses in hemoglobin, lowering of the M‐protein concentration, and reduction of azotemia. Significant benefits attributable to prednisone were not demonstrated in the group receiving 0.3 mg/kg. Good responses have been shown to produce improved survival. The combination of melphalan and prednisone is effective in producing good responses, but the dose of steroids is important. A dose of prednisone of 0.6 mg/kg in gradually decreasing doses has been found to be effective in production of good responses, especially in the uremic patient.